Is Cell Point overvalued or undervalued?

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all of which suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.
In comparison to peers, Cell Point's PE ratio significantly exceeds that of PTC India, which stands at 7.52, and even Elitecon International, which is at 309.88, indicating that Cell Point is priced much higher relative to its earnings potential. Additionally, while Cell Point's price has recently seen a 8.33% increase over the past week, it has underperformed the Sensex with a year-to-date decline of 27.1% compared to the Sensex's gain of 9.58%. This further reinforces the notion that Cell Point is currently overvalued in the market.